Pacific Biosciences of California Inc (NASDAQ:PACB) has a beta value of 1.95 and has seen 2.04 million shares traded in the recent trading session. The company, currently valued at $537.34M, closed the recent trade at $1.93 per share which meant it gained $0.13 on the day or 7.19% during that session. The PACB stock price is -451.81% off its 52-week high price of $10.65 and 39.9% above the 52-week low of $1.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 12.5 million shares traded. The 3-month trading volume is 9.47 million shares.
The consensus among analysts is that Pacific Biosciences of California Inc (PACB) is Buy stock at the moment, with a recommendation rating of 2.19. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 11 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.18.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Sporting 7.19% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PACB stock price touched $1.93 or saw a fall of -0.49%. Year-to-date, Pacific Biosciences of California Inc shares have moved -80.33%, while the 5-day performance has seen it change 22.89%. Over the past 30 days, the shares of Pacific Biosciences of California Inc (NASDAQ:PACB) have changed 9.01%. Short interest in the company has seen 50.41 million shares shorted with days to cover at 6.88.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 35.67% from the levels at last check today. The projected low price target is $2.0 while the price target rests at a high of $4.0. In that case, then, we find that the latest price level in today’s session is -107.25% off the targeted high while a plunge would see the stock gain -3.63% from the levels at last check today.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Figures show that Pacific Biosciences of California Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 2.90% over the past 6 months, with this year growth rate of 18.02%, compared to 15.40% for the industry. Revenue growth from the last financial year stood is estimated to be -22.43%.
12 analysts offering their estimates for the company have set an average revenue estimate of 40.71M for the current quarter. 10 have an estimated revenue figure of 43.08M for the next ending quarter. Year-ago sales stood 58.36M and 38.81M respectively for this quarter and the next, and analysts expect sales will shrink by -30.24% for the current quarter and -22.43% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.76% over the past 5 years. Earnings growth for 2024 is a modest -12.86% while over the next 5 years, the company’s earnings are expected to decrease by -1.00%.
PACB Dividends
Pacific Biosciences of California Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
Insiders own 1.85% of the company shares, while shares held by institutions stand at 83.08% with a share float percentage of 84.64%. Investors are also buoyed by the number of investors in a company, with Pacific Biosciences of California Inc having a total of 318.0 institutions that hold shares in the company. The top two institutional holders are ARK INVESTMENT MANAGEMENT LLC with over 33.21 million shares worth more than $45.5 million. As of 2024-06-30, ARK INVESTMENT MANAGEMENT LLC held 12.3202% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 26.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $35.62 million and represent 9.6443% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. As of Oct 31, 2024, the former fund manager holds about 6.91% shares in the company for having 18.94 shares of worth $36.45 million while later fund manager owns 12.39 shares of worth $23.85 million as of Oct 31, 2024, which makes it owner of about 4.52% of company’s outstanding stock.
